JPRN-UMIN000021324
Completed
Phase 1
Feasibility and safety of neoadjuvant intravenous and intraperitoneal chemotherapy for peritoneal metastasis from colorectal or appendiceal cancer - Feasibility and safety of neoadjuvant intravenous and intraperitoneal chemotherapy for peritoneal metastasis from colorectal or appendiceal cancer
ational Center for Global Health and Medicine0 sites20 target enrollmentMarch 3, 2016
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Peritoneal metastasis from colorectal or appendiceal cancer
- Sponsor
- ational Center for Global Health and Medicine
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Metastasis to distant organ sites (such as liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study with hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled studyModerate-to-severe COVID-19 pneumoniaMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-003614-13-ITImmuneMed Inc.105
Not yet recruiting
Not Applicable
A study to evaluate the efficacy & safety of intravenous Ferric Carboxy Maltose in breast cancer patients with iron deficiency anemiaCTRI/2023/11/059490Emcure Pharmaceuticals Ltd
Completed
Phase 2
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patientsIRCT20151227025726N20Shahid Beheshti University of Medical Sciences80
Recruiting
Phase 2
The Efficacy and Feasibility Study of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer (Est-Neo)Rectal CancerJPRN-UMIN000005654Gastro-intestinal Sugery Division, Kyoto University Hospital55
Recruiting
Phase 2
Investigating the effect of the bone marrow-drived mesenchymal stem cells in MS patients under fingolimod therapy.IRCT20191004044975N1Vice-presidency for science and technology120